Perrigo’s Generic Portfolio Boosted
Good news flowed in at Perrigo Company (NASDAQ:PRGO) when the U.S. Food and Drug Administration (FDA) cleared its generic version of KV Pharmaceutical Company’s vaginal cream Gynazole·1. Final approval was granted by the U.S. regulatory body for the local treatment of vulvovaginal candidiasis. Apart from gaining FDA approval to sell its generic version of the [...]
Good news flowed in at Perrigo Company (NASDAQ:PRGO) when the U.S. Food and Drug Administration (FDA) cleared its generic version of KV Pharmaceutical Company’s vaginal cream Gynazole·1. Final approval was granted by the U.S. regulatory body for the local treatment of vulvovaginal candidiasis.
Apart from gaining FDA approval to sell its generic version of the product, Perrigo also enjoys a six month marketing exclusivity period regarding Gynazole·1 since it was the first company to file an … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards